Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue
Pfizer's revenue swung sharply lower before stabilizing, while Bristol Myers Squibb kept climbing steadily—a divergence that matters for long-term investors.
Bristol Myers Squibb and Pfizer are both major players in the prescription medicine industry, generating revenue primarily through the development and sale of various pharmaceuticals. However, their approaches to revenue generation differ, with Bristol Myers Squibb focusing on oncology, immunology, and cardiovascular diseases, while Pfizer concentrates on a broader portfolio of medicines and vaccines.
Over the past eight quarters, both companies have experienced drops in revenue due to the seasonal nature of their businesses. This seasonality is often attributed to patients and doctors making more significant purchases towards the end of the year when they have met their health insurance deductibles.
Despite these drops, both companies show upward trends in comparable quarters year over year, which is generally a positive sign for potential investors. Bristol Myers Squibb has made positive strides with its newer growth brands gaining traction and some promising candidates in the pipeline. However, the stock is currently considered cheap, which may be due to investors having already priced in many of the upcoming difficulties, resulting in a softened downside but not making it an obvious buy at the moment.
Pfizer, on the other hand, is currently seeing a slight slump in revenue for its current fiscal year, while Bristol Myers Squibb's revenue is projected to edge up by 3% to $49.9 billion. Although Pfizer's net income is expected to rise by $1.2 billion to $8.9 billion, the company faced a post-COVID 19 letdown due to ebbing pandemic-related demand. However, Pfizer has shown resilience this year, with a beat on sales and net income in its first quarter of the year.
This improvement can be attributed to Pfizer's expansion efforts, such as its recent acquisition of oncology specialist Seagen, which reported a 20% growth in product sales. Despite this, based solely on revenue trends, Bristol Myers Squibb appears to be on a better track at the moment. Investors should consider this information in conjunction with other factors when making investment decisions.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
